arsenate laser. The other hand received a sham laser treatment designed so that neither therapist nor patient could distinguish the active laser from the sham laser. Each patient received 12 treatments over four weeks. The following parameters were measured: pain as assessed by visual analogue scale; range of joint movements; grip strength; duration of early morning stiffness, joint circumference, Jebsen's hand assessment; drug usage; total swollen joint counts; Arthritis Impact Measurement Scales; three phase bone scans; haematological and serological tests.
Results-A total of 72% of patients reported pain reliefbut this reduction was reported equally in both hands. No significant changes were seen in other clinical, functional, scintigraphic, or laboratory features. Neither patients nor staff were able to detect which hand was treated with the active laser. Conclusion-When this specific laser and dose regimen was used, low power laser treatment had no objective effect on patients with rheumatoid arthritis. It did appear to produce analgesia through a powerfil placebo effect.
(Ann Rheum Dis 1993; 52: 703-706) Low power laser treatment is increasingly used as a modality of physical therapy in the management of a variety of musculoskeletal diseases, including rheumatoid arthritis (RA). -" A variety of laser sources are used, such as gallium-aluminium-arsenate, heliumneon, gallium-arsenate, with power outputs of 50 mW or less. No thermal energy is delivered, and the laser may be within the visible light spectrum or invisible.
In patients with RA, previous workers have reported that laser treatment produces both local and systemic changes, including decreased joint pain, decreased joint swelling, increased functional activity, decreased duration of early morning stiffness, and improved laboratory parameters including erythrocyte sedimentation rate.' 3 No mechanism of action has been defined but photochemical reactions, particularly in the mitochondria, have been suggested. 12-13 The optimal wavelength and dosage for the treatment of RA is unknown as, depending on the experimental system, either inhibition or stimulation of selected cell functions has been reported.'4 A wide range of differing wavelengths and doses has been used in published reports making it difficult to compare studies (table) .
In our hospital, treatment with a galliumaluminium-arsenate laser appeared to produce significant benefit in patients with active RA in the hands. We therefore designed a double blind trial to investigate local changes in the hands of patients with RA, and to document any systemic changes. A protocol employing sham laser treatment to one hand was preferred rather than the use of a non-treatment group, so that each patient had an opportunity to benefit from active treatment, and each patient could compare changes in their two hands. A course of 12 laser treatments was given over a four week period. The active and sham laser probes were identical in external appearance except for a code label, and no visible light, heat, or vibration was detectable from either the active or the placebo probe. The code was kept secret by an uninvolved staff member until all data were analysed.
Patients and methods
The treatment was delivered by means of medial and lateral approaches and with the joint held in a loose packed position-that is, 450 of flexion or neutral position. The treated joints were the metacarpophalangeal, proximal interphalangeal, and the interphalangeal joint of the thumb. A total of 12 Patients were scanned one day before and two days after treatment. On both occasions, patients were injected with 800-1000 MBq of technetium-99m labelled methylene disphosphonate (Radpharm, Australia) with blood pool images taken two to four minutes after injection and delayed images taken three hours after injection. Palmar and dorsal views of the hands were obtained in both blood pool and delayed studies. Imaging was performed using a gammacamera with a small field of view connected to a dedicated nuclear medicine computer (GE Starcam, Milwaukee, WI, United States) with 256 X 256 matrix acquisition, low energy, all purpose collimator, and 10 minutes of acquisition time per image. All joints in each hand were scored on both blood pool and delayed studies by two nuclear medicine physicians. The scoring system was -1 for decreased joint activity, 0 for normal activity, and +1 for increased activity. Differences between observers were reviewed and a consensus decision was recorded.
The scans were scored in random order by physicians who were unaware of whether they were pretreatment or posttreatment or which hand had received active treatment.
For statistical analysis, the changes in the treated hands were compared with the changes in the sham treated hands, using Wilcoxon sign rank tests. Correction for multiple measures indicated that a p value of <0 003 was required for statistical significance.
Results

CLINICAL PARAMETERS
Eighteen of 25 patients (72%) reported improvement in pain, but pain (as measured by the visual analogue scale) was reduced in both treated and sham treated hands after laser intervention (p<0-001 for comparison before and after treatment). The figure shows the mean values for pain per week, where weeks 0 and 5 are assessment only. There was no difference in the extent of pain relief in the treated hands and the sham treated hands. To assess the patients's ability to discriminate between active laser and placebo they were designed this double blind trial to document any clinical or laboratory changes. We expected a strong placebo effect from the intensive contact with the therapist, combined with the 'high tech' appearance of the laser equipment, and we were therefore careful to ensure that both patient and therapist were ignorant of which treatment was being given.
The impressive change was the reduction in pain which was reported by 18/25 (72%)
subjects, but these changes were reported equally in both hands. Laboratory studies were unchanged making it unlikely that a systemic effect from laser treatment of one hand could have reduced pain in the other. Moreover, detailed function measures, including functional assessments of each hand, showed no changes in either the treated or sham treated hands, despite the reported reduction in pain. A placebo effect is clearly the most likely explanation for the reported analysis. Depending on the type of intervention, placebo responses varying from 6-2% to 80% have been described. 20 21 Typically, uncontrolled studies of laser treatment in RA have claimed dramatic improvement with pain reduction of more than 90%. One such paper conceded, however, that measures which were less placebo-sensitive, such as range of movement, 'did not always show rates of improvement similar to effectiveness of pain removal'.4 At least four double blind trials have been previously published. 1-3 22 In each study a strong placebo effect was noted, with improvement in sham treated joints, usually in pain measurement, but sometimes in strength and range of movement.
Palmgren et al3 used the same type of laser as in our study but the dose (3-6 J/cm2) was slightly smaller. They showed significant improvements in grip strength, movement, joint swelling, and the duration of early morning stiffness compared with control patients who had sham treatment. Pain improved in both their patients' hands, but more so in their treated hands. Both erythrocyte sedimentation rate and total leucocyte counts fell with a significant trend. In Palmgren's study half the patients received active laser treatment and in half, placebo laser was used. We treated one hand and sham treated the other, and it is possible that, in our study, some systemic effect occurred that 'flowed over' from the actively treated to the placebo treated hand. Arguing against this possibility was the lack of change in erythrocyte sedimentation rate, or any other parameter measured. In addition, we found no change in any objective measurement or functional assessment. Despite the differences in design and dosage, it is difficult to reconcile our negative results with Palmgren's dramatic improvements.
Bliddal et all and Goldman et al2 used the same design as our study, but with different lasers. Bliddal's helium-neon laser produced a burning sensation in the actively treated joints of some patients, which would invalidate the blind element of the trial. Even so, less than half their patients reported pain relief, and there was no change in duration of early morning stiffness or joint range of movement.
No changes in laboratory parameters were found. The authors concluded that laser treatment was of limited value.
Goldman's study used a Q-switch neodymium laser which delivers pulsatile irradiation at a fairly high output (15 J/cm2 in 30 ns).2 All patients reported stinging from the laser, and more than 1 0% reported erythema or hyperpigmentation at the actively treated joints, invalidating efforts at making the trial blind. Both the treated and sham treated hands showed improvement for a range of measures: heat; erythema; pain; swelling; and tenderness. Erythema and pain were reported to have improved more in the treated hand than the placebo treated hand. Grasp and pinch strength were reported as more objective measures of improvement in the treated hands, but the probability values were not correctecd for multiple measures and were, in each case, p=002 and therefore unlikely to be significant. Similarly, the reported change in platelet aggregation (p=0025), which was proposed to indicate a systemic effect, would not be significant if the rate for each experiment were considered.
Walker et a122 reported significant pain reductions only in the treated patients, but this required nine weeks of treatment. Conceivably our actively treated patients might have improved to a significant degree with more prolonged treatment.
Photochemical reactions, particularly in vitamin D metabolism, melanin, and in the retina, are well described and there seems to be no a priori reason why laser treatment could not exert an effect on one or more of the many pathways that lead to pain and inflammation in the arthritic hand. We found no objective benefit with the dose regimen we used, but cannot exclude the possibility of efficacy with another regimen. The gallium-aluminiumarsenate lasers are safe, and have been efficacious in at least one well controlled trial,3 and it therefore seems prudent to use such lasers in further trials. We have demonstrated the absolute necessity of placebo controls in low power laser treatment research.
